# Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

> **NCT00352131** · PHASE1 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Non-colorectal Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** HuC242-DM4

## Key facts

- **NCT ID:** NCT00352131
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2010-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352131, "Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00352131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*